189 related articles for article (PubMed ID: 1195128)
1. Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.
Gugler R; Lain P; Azarnoff DL
J Pharmacol Exp Ther; 1975 Dec; 195(3):416-23. PubMed ID: 1195128
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear intestinal first-pass metabolism of salicylamide in dogs after portacaval transposition.
Pond SM; Waschek JA; Mahacha V; Fielding RM; Effeney DJ; Tozer TN
J Pharmacol Exp Ther; 1988 Apr; 245(1):291-3. PubMed ID: 3361447
[TBL] [Abstract][Full Text] [Related]
3. Non-linear hepatic first-pass metabolism of salicylamide in dogs after portacaval transposition.
Pond SM; Mahachai V; Effeney DJ; Tozer TN
J Pharmacokinet Biopharm; 1988 Apr; 16(2):161-4. PubMed ID: 3418493
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
Neal EA; Meffin PJ; Gregory PB; Blaschke TF
Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent bioavailability and metabolism of salicylamide in dogs.
Waschek JA; Rubin GM; Tozer TN; Fielding RM; Couet WR; Effeney DJ; Pond SM
J Pharmacol Exp Ther; 1984 Jul; 230(1):89-93. PubMed ID: 6747835
[TBL] [Abstract][Full Text] [Related]
6. Effect of portacaval shunt on drug disposition in patients with cirrhosis.
Pomier-Layrargues G; Huet PM; Villeneuve JP; Marleau D
Gastroenterology; 1986 Jul; 91(1):163-7. PubMed ID: 3710065
[TBL] [Abstract][Full Text] [Related]
7. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites.
Orloff MJ; Orloff MS; Orloff SL; Girard B
J Am Coll Surg; 1997 Jun; 184(6):557-70. PubMed ID: 9179111
[TBL] [Abstract][Full Text] [Related]
8. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition.
Lo MW; Effeney DJ; Pond SM; Silber BM; Riegelman S
J Pharmacol Exp Ther; 1982 May; 221(2):512-5. PubMed ID: 7077541
[TBL] [Abstract][Full Text] [Related]
9. Effect of the duration of infusion on the disposition of lidocaine in dogs.
LeLorier J; Moisan R; Gagné J; Caillé G
J Pharmacol Exp Ther; 1977 Dec; 203(3):507-11. PubMed ID: 925956
[TBL] [Abstract][Full Text] [Related]
10. [Drug dosing in chronic hepatic disease (author's transl)].
Gugler R; Eichelbaum M
Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
[TBL] [Abstract][Full Text] [Related]
11. Prehepatic and hepatic first-pass metabolism of lorcainide in rats.
Plänitz V; Grönniger J; Jähnchen E
Arzneimittelforschung; 1985; 35(6):923-6. PubMed ID: 4026917
[TBL] [Abstract][Full Text] [Related]
12. Temporary beneficial effect of arterialization of the liver in cirrhotic dogs with a portacaval shunt. A preliminary report.
Terpstra OT; van Vroonhoven TJ; Noordhoek J; ten Kate FJ; Wilson JH
Eur Surg Res; 1982; 14(5):333-43. PubMed ID: 7128651
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of rapid entry and a cellular binding space for salicylamide in perfused rat liver: a multiple indicator dilution study.
Pang KS; Barker F; Schwab AJ; Goresky CA
J Pharmacol Exp Ther; 1994 Jul; 270(1):285-95. PubMed ID: 8035326
[TBL] [Abstract][Full Text] [Related]
14. Effect of route of administration on competitive drug biotransformation interaction: salicylamide-ascorbic acid interaction in rats.
Houston JB; Levy G
J Pharmacol Exp Ther; 1976 Aug; 198(2):284-94. PubMed ID: 948026
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent sulfoconjugation of salicylamide in dogs: effect of sulfate depletion or administration.
Waschek JA; Fielding RM; Pond SM; Rubin GM; Effeney DJ; Tozer TN
J Pharmacol Exp Ther; 1985 Aug; 234(2):431-4. PubMed ID: 4020679
[TBL] [Abstract][Full Text] [Related]
16. Rectal bioavailability of lidocaine in the dog: evaluation of first-pass elimination.
Ritschel WA; Grummich KW; Hussain AS; Denson DD; Ritschel BE
Methods Find Exp Clin Pharmacol; 1987 Aug; 9(8):497-502. PubMed ID: 3695734
[TBL] [Abstract][Full Text] [Related]
17. [Drug metabolism in patients with liver disease (author's transl)].
Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
[TBL] [Abstract][Full Text] [Related]
18. Effect of product inhibition on elimination kinetics of ethoxybenzamide in rabbits. Analysis by physiological pharmacokinetic model.
Lin JH; Sugiyama Y; Hanano M; Awazu S
Drug Metab Dispos; 1984; 12(2):253-6. PubMed ID: 6144493
[TBL] [Abstract][Full Text] [Related]
19. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt.
van der Graaff M; Vermeulen NP; Joeres RP; Breimer DD
Pharmacology; 1984; 29(2):99-109. PubMed ID: 6473507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
